Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdv.12699 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patient-reported outcomes in patients with peristomal pyoderma gangrenosum: A single-center prospective study.
JAAD Case Rep
January 2025
Department of Dermatology, Oregon Health and Science University, Portland, Oregon.
Comments on "Impact of delay of diagnosis of pyoderma gangrenosum on healing outcomes and healthcare utilization: a prospective cohort study".
J Am Acad Dermatol
January 2025
Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address:
Response to "Comments on "Impact of delay of diagnosis of pyoderma gangrenosum on healing outcomes and healthcare utilization: a prospective cohort study"".
J Am Acad Dermatol
January 2025
Department of Dermatology, Oregon Health and Science University, Portland, Oregon. Electronic address:
Rapid and Sustained Resolution of Peristomal Pyoderma Gangrenosum With Aerosol Steroid Treatment.
J Wound Ostomy Continence Nurs
January 2025
Kyriaki Stefania Mitsaki, MBBCh, BSc (Hons), MSc, MRCP, Department of Dermatology, Northwick Park Hospital, London North West University Hospital NHS Trust, London, UK.
Background: Peristomal pyoderma gangrenosum (PPG) is a non-infectious neutrophilic dermatosis most commonly seen in the context of ostomies in inflammatory bowel disease. The lack of established treatment guidelines and high-quality evidence in the form of randomized controlled trials present a major challenge in PPG management, owing to the rarity of the condition. Treatment can be further complicated by difficulties in maintaining the stoma pouch seal with conventional topical corticosteroids.
View Article and Find Full Text PDFSuccessful treatment of etanercept- and adalimumab-resistant pyoderma gangrenosum with spesolimab, moderate-dose corticosteroids, and minocycline.
J Dermatolog Treat
December 2025
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Purpose: Pyoderma gangrenosum (PG) is a rare, neutrophilic dermatosis characterized by rapidly developing, painful ulcers. This study explores the potential of spesolimab, an anti-IL-36R antibody, as a therapeutic option for refractory PG.
Materials And Methods: We report a case of a 48-year-old male with refractory PG who failed to respond to etanercept and adalimumab.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!